Literature DB >> 9539133

Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abeta1-42/43 expression.

S Qian1, P Jiang, X M Guan, G Singh, M E Trumbauer, H Yu, H Y Chen, L H Van de Ploeg, H Zheng.   

Abstract

Mutations in presenilin 1 (PS1) are linked to early onset of familial Alzheimer's disease (FAD) and are shown to foster production of Abeta1-42/43 in FAD patients and transgenic mice. PS1 null mice are embryonic lethal and exhibit axial skeleton malformation and CNS defects. We show that transgenic mouse lines expressing either the wild-type human PS1 protein or human PS1 with the A246E FAD mutation can rescue the PS1 knockout mouse from embryonic lethality to similar degrees, indicating that the mutation does not lead to loss of PS1 function during development. Furthermore, a 50% reduction of PS1 activity in PS1(+/-) mice does not lead to Abeta1-42/43 increase, whereas expression of human mutant PS1 on murine PS1 null background is sufficient to elevate Abeta1-42/43, supporting a gain-of-function activity as the result of the PS1 mutation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9539133     DOI: 10.1016/s0896-6273(00)80999-x

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  51 in total

1.  From Alzheimer's disease to skin tumors: the catenin connection.

Authors:  D Hartmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

2.  Interactions between fibroblast growth factors and Notch regulate neuronal differentiation.

Authors:  C H Faux; A M Turnley; R Epa; R Cappai; P F Bartlett
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

Review 3.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

Review 4.  Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics.

Authors:  P C Wong; H Cai; D R Borchelt; D L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

5.  Generation of mice expressing the human glucagon receptor with a direct replacement vector.

Authors:  L L Shiao; M A Cascieri; M Trumbauer; H Chen; K A Sullivan
Journal:  Transgenic Res       Date:  1999-08       Impact factor: 2.788

6.  Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer's disease mutations.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Anne B Rocher; Athena Ching-Jung Wang; William G M Janssen; Tony Flores; Gissel M Perez; James Schmeidler; Dara L Dickstein; Patrick R Hof; Gregory A Elder
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

7.  Design and characterization of a new cell-permeant inhibitor of the beta-secretase BACE1.

Authors:  Solveig Lefranc-Jullien; Vincent Lisowski; Jean-François Hernandez; Jean Martinez; Frédéric Checler
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

8.  Modeling presenilin-dependent familial Alzheimer's disease: emphasis on presenilin substrate-mediated signaling and synaptic function.

Authors:  Angèle T Parent; Gopal Thinakaran
Journal:  Int J Alzheimers Dis       Date:  2010-07-20

Review 9.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

10.  Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation.

Authors:  María-Ximena Silveyra; Geneviève Evin; María-Fernanda Montenegro; Cecilio J Vidal; Salvador Martínez; Janetta G Culvenor; Javier Sáez-Valero
Journal:  Mol Cell Biol       Date:  2008-02-25       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.